# PALISADES-1 (NCT04989803)

> Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

No report yet. It can be ordered.

- Drugs tested: KITE-363; KITE-753
- Indication: relapsed and/or refractory B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04989803
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Kite, A Gilead Company
- Conditions: Relapsed and/or Refractory B-cell Lymphoma
- Interventions: Cyclophosphamide; Fludarabine; KITE-363; KITE-753
- Enrollment: 247
- Primary outcome: Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753
- Primary outcome: Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.
- Primary outcome: Phase 2: ORR as per central assessment for KITE-753

## Indexed commentary on PALISADES-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=palisades-1-nct04989803